

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Duality Biotherapeutics, Inc.

映恩生物

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 9606)

VOLUNTARY ANNOUNCEMENT

INCLUSION AS A CONSTITUENT OF HANG SENG COMPOSITE INDEX AND INCLUSION IN THE STOCK LIST OF STOCK CONNECT SOUTHBOUND TRADING LINK

This announcement is made by Duality Biotherapeutics, Inc. (the “**Company**”) to provide its shareholders and potential investors with information in relation to the latest development regarding the Company.

The board (the “**Board**”) of directors of the Company is pleased to announce that, with effect from September 8, 2025, the shares (the “**Shares**”) of the Company will be included (i) as a constituent stock of the Hang Seng Composite Index by Hang Seng Indexes Company Limited and (ii) in the list of eligible shares of the Southbound Trading Link of the Shanghai-Hong Kong Stock Connect.

The inclusion of the Shares as eligible securities under the Hang Seng Composite Index and the Shanghai-Hong Kong Stock Connect represents the capital market’s high recognition of the Company’s performance and value and allows eligible investors in mainland China to directly invest in the Shares listed on The Stock Exchange of Hong Kong Limited via the Shanghai Stock Exchange. It is expected that the inclusion will further expand the Company’s investor base and potentially increase the trading liquidity for the Shares.

By order of the Board

Duality Biotherapeutics, Inc.

Dr. ZHU Zhongyuan

*Chairman of the Board, Executive
Director and Chief Executive Officer*

Hong Kong, September 7, 2025

As at the date of this announcement, the Board comprises (i) Dr. ZHU Zhongyuan, Mr. ZHANG Shaoren and Ms. SI Wen as executive directors; (ii) Mr. CAI Zhiyang and Dr. YU Tao as non-executive directors; and (iii) Mr. XIE Dong, Mr. GAO Fengyong and Ms. CHUAI Shuyin as independent non-executive directors.